Breast Cancer Overview: Types, Stages, and Treatment Paths

Not All Breast Cancers Are the Same

The most common type is invasive ductal carcinoma, or IDC. It starts in the milk ducts and breaks through into surrounding breast tissue. About 70-80% of breast cancer diagnoses are IDC. Then there's invasive lobular carcinoma, which starts in the lobules—the glands that produce milk. It's trickier to catch on a mammogram because it tends to spread in a single-file pattern rather than forming a distinct lump.

There are rarer types too: inflammatory breast cancer moves fast and causes redness and swelling rather than a lump—it's often mistaken for an infection at first. Triple-negative breast cancer doesn't have estrogen receptors, progesterone receptors, or HER2 receptors, which means hormone-blocking drugs won't work for it. And HER2-positive cancers overexpress a growth-promoting protein, which is actually a targetable weakness now that drugs like trastuzumab exist.

Why does this matter to you? Because 'breast cancer' on a pathology report tells your oncologist almost nothing on its own. The receptor profile—that combination of ER, PR, and HER2—drives the treatment plan. Two women with stage 2 breast cancer sitting in the same waiting room might be heading toward completely different therapies.

How Staging Actually Works

Staging runs from 0 to IV and describes how far the cancer has spread. Stage 0, also called DCIS (ductal carcinoma in situ), is noninvasive—cancer cells are confined to the duct lining. Stage I means the tumor is small, 2 centimeters or less, and hasn't spread to lymph nodes. By stage II, either the tumor is larger or a few nearby lymph nodes are involved. Stage III means significant lymph node involvement or spread to nearby structures like the chest wall. Stage IV is metastatic—cancer has reached distant organs like the lungs, liver, or bones.

Staging isn't just about tumor size, though. Since 2018 the American Joint Committee on Cancer incorporated biomarkers into the staging system. So a woman with a small tumor that is strongly hormone-receptor-positive and low-grade might be staged lower than her tumor size alone would suggest, because the biology is favorable. And a larger tumor that's high-grade and triple-negative might be staged higher. This biological staging is one reason your oncologist might quote you a stage that doesn't match exactly what you read on a generic chart online.

Don't try to map your prognosis entirely from the stage number. Five-year survival statistics are population averages from data collected years ago. Treatment has improved a lot. Talk to your oncologist about what the stage means for your specific subtype.

• Stage 0: DCIS, non-invasive, confined to duct
• Stage I: tumor ≤2 cm, no or minimal node involvement
• Stage II: larger tumor or limited lymph node spread
• Stage III: extensive nodes or local tissue involvement
• Stage IV: distant metastasis (lungs, liver, bones, brain)

Surgery and Radiation: The Local Treatments

Surgery is usually the first conversation. You'll hear about lumpectomy—removing just the tumor and a margin of healthy tissue—versus mastectomy, which removes the entire breast. For many early-stage cases, a lumpectomy followed by radiation gives survival outcomes equal to mastectomy. That's worth repeating because a lot of patients assume 'more surgery equals more safety,' and the research just doesn't support that across the board.

Radiation typically follows a lumpectomy to eliminate any cancer cells that might have been left behind. The standard course used to be 5-6 weeks of daily treatment. Many centers now offer hypofractionated radiation—15-16 sessions instead—which delivers slightly larger daily doses and has equivalent outcomes for most patients. Ask your radiation oncologist if you're a candidate, because fewer trips to a treatment center matters when you're working or caring for kids.

Sentinel lymph node biopsy is usually done during surgery. The surgeon injects a dye or radioactive tracer to identify the first lymph nodes cancer would drain to, and removes just those. If they're clear, more extensive lymph node removal is usually unnecessary. This has dramatically reduced cases of lymphedema—the arm swelling that used to be much more common after breast cancer surgery.

Systemic Treatments: Chemo, Targeted Therapy, and Immunotherapy

Chemotherapy is used when cancer has spread to lymph nodes, when the tumor is large, or when genetic tests like Oncotype DX suggest high recurrence risk. It's given before surgery (neoadjuvant) or after (adjuvant). Common regimens include AC-T—doxorubicin, cyclophosphamide, then paclitaxel. Not everyone needs chemotherapy. If you have small, hormone-receptor-positive, HER2-negative cancer, a genomic test score might confirm you can safely skip it and do just fine with hormone-blocking medication alone.

HER2-positive cancers get targeted therapy—trastuzumab (Herceptin) is the best known, usually given alongside chemo and continued for a year. Triple-negative breast cancer, which used to have the fewest treatment options, now has immunotherapy added for high-risk cases. Pembrolizumab in combination with chemo has improved outcomes for early-stage triple-negative disease.

These drugs are powerful and they have real side effects. Fatigue, neuropathy from taxanes, cardiac monitoring with trastuzumab—these are real. Ask your care team about each one specifically, because the severity varies by drug and by individual. Don't suffer through side effects silently. There are often good management strategies.

Hormone-Blocking Therapy: Where Tamoxifen and Raloxifene Come In

About 75% of breast cancers are hormone-receptor-positive, meaning estrogen or progesterone fuels their growth. Blocking that fuel source is one of the most effective tools we have. Tamoxifen is a selective estrogen receptor modulator—it binds to estrogen receptors in breast tissue and blocks estrogen from activating them. It's been used for decades and is standard for premenopausal women with hormone-receptor-positive breast cancer. Treatment typically runs 5-10 years, and it cuts recurrence risk significantly. It can also be used as risk-reduction therapy in high-risk women who haven't been diagnosed yet.

Postmenopausal women are often switched to aromatase inhibitors like anastrozole or letrozole, which block estrogen production at the source rather than at the receptor. But tamoxifen is still appropriate for some postmenopausal patients, particularly those who can't tolerate aromatase inhibitors.

Raloxifene is a different SERM, primarily known as a treatment for osteoporosis. But it's also FDA-approved to reduce the risk of invasive breast cancer in postmenopausal women at high risk—think someone with a strong family history or high Tyrer-Cuzick score. The STAR trial compared raloxifene to tamoxifen for risk reduction and found them roughly equivalent at reducing invasive breast cancer, with raloxifene causing fewer uterine cancers and blood clots. It's not a treatment for existing breast cancer—that distinction matters. Talk to your doctor about whether either medicine is right for your situation.

• Tamoxifen: ER-positive breast cancer treatment and risk reduction
• Raloxifene: risk reduction in high-risk postmenopausal women
• Both are SERMs—they act on estrogen receptors selectively
• Duration for tamoxifen: typically 5-10 years post-diagnosis
• Side effects differ: tamoxifen has higher uterine cancer risk; raloxifene has slightly lower

Risk Reduction: What Can You Actually Do?

Genetics play a role—BRCA1 and BRCA2 mutations substantially increase lifetime risk. If you have close relatives with breast or ovarian cancer, ask your doctor about genetic counseling. But most breast cancers occur in women with no family history. Modifiable risk factors include alcohol consumption (even moderate drinking raises risk slightly—about a 7-10% increase per drink per day), excess body weight after menopause, physical inactivity, and postmenopausal hormone therapy with combined estrogen-progestin.

Breastfeeding, if you're able, is associated with modest risk reduction. Regular exercise—the numbers suggest 150 minutes of moderate activity per week—helps with both prevention and outcomes after diagnosis. These aren't guarantees. You can do everything right and still get breast cancer. But they move the odds in the right direction.

High-risk women should have a conversation with their doctor about preventive medications. That's where tamoxifen and raloxifene come into the picture for primary prevention. This is a real conversation worth having, not just a footnote.

Screening: Who Gets What and When

Annual mammograms starting at 40 are recommended by the American College of Radiology. The US Preventive Services Task Force updated its guidance in 2024 to recommend starting at 40 as well, catching up with what many breast radiologists had been saying for years. If you're average-risk and in your 40s, you should be getting screened annually.

High-risk women—those with BRCA mutations, a strong family history, or prior chest radiation before age 30—often get supplemental MRI screening in addition to mammograms. Dense breasts, which show up in about 40% of women, can make mammograms harder to read. Some states require notification when dense breast tissue is detected, and supplemental ultrasound or MRI may be worth discussing with your doctor.

Early detection genuinely saves lives here. A stage I diagnosis has a 5-year relative survival rate above 99%. Don't skip your mammogram because you're busy or nervous about results. Being busy is not a good enough reason.

Common questions